DENTSPLY SIRONA Inc. (NASDAQ:XRAY) Given Consensus Rating of “Reduce” by Analysts

Shares of DENTSPLY SIRONA Inc. (NASDAQ:XRAY) have been assigned a consensus recommendation of “Reduce” from the fourteen ratings firms that are currently covering the stock, Marketbeat.com reports. Three research analysts have rated the stock with a sell recommendation, nine have given a hold recommendation and two have given a buy recommendation to the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $14.8333.

Several equities analysts have weighed in on the company. Weiss Ratings restated a “sell (d-)” rating on shares of DENTSPLY SIRONA in a report on Wednesday, January 21st. Barrington Research reissued an “outperform” rating and issued a $14.00 target price on shares of DENTSPLY SIRONA in a report on Monday, January 5th. Evercore ISI decreased their price target on shares of DENTSPLY SIRONA from $17.00 to $13.00 and set an “in-line” rating on the stock in a research note on Wednesday, October 8th. UBS Group dropped their price objective on shares of DENTSPLY SIRONA from $24.00 to $23.00 and set a “buy” rating for the company in a research note on Tuesday, October 28th. Finally, Robert W. Baird decreased their target price on shares of DENTSPLY SIRONA from $14.00 to $12.00 and set a “neutral” rating on the stock in a research report on Tuesday, December 16th.

DENTSPLY SIRONA Trading Down 0.1%

Shares of XRAY opened at $12.72 on Tuesday. DENTSPLY SIRONA has a 1 year low of $9.85 and a 1 year high of $20.59. The company has a 50 day simple moving average of $11.57 and a two-hundred day simple moving average of $12.84. The company has a debt-to-equity ratio of 1.36, a current ratio of 1.47 and a quick ratio of 0.99. The firm has a market cap of $2.54 billion, a P/E ratio of -2.88, a price-to-earnings-growth ratio of 1.00 and a beta of 1.00.

DENTSPLY SIRONA (NASDAQ:XRAY) last posted its earnings results on Thursday, November 6th. The medical instruments supplier reported $0.37 earnings per share for the quarter, missing the consensus estimate of $0.45 by ($0.08). DENTSPLY SIRONA had a negative net margin of 24.34% and a positive return on equity of 17.10%. The company had revenue of $904.00 million for the quarter, compared to analysts’ expectations of $900.33 million. During the same period in the previous year, the business posted $0.50 earnings per share. The business’s revenue was down 4.9% on a year-over-year basis. DENTSPLY SIRONA has set its FY 2025 guidance at 1.600-1.600 EPS. On average, equities analysts expect that DENTSPLY SIRONA will post 1.84 earnings per share for the current fiscal year.

DENTSPLY SIRONA Dividend Announcement

The business also recently announced a quarterly dividend, which was paid on Friday, January 9th. Stockholders of record on Friday, December 26th were issued a $0.16 dividend. The ex-dividend date was Friday, December 26th. This represents a $0.64 dividend on an annualized basis and a dividend yield of 5.0%. DENTSPLY SIRONA’s payout ratio is -14.48%.

Insiders Place Their Bets

In related news, Director Gregory T. Lucier sold 82,200 shares of the firm’s stock in a transaction on Monday, December 8th. The stock was sold at an average price of $11.14, for a total value of $915,708.00. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Insiders own 0.52% of the company’s stock.

Hedge Funds Weigh In On DENTSPLY SIRONA

A number of large investors have recently made changes to their positions in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. purchased a new position in shares of DENTSPLY SIRONA during the first quarter valued at approximately $26,000. Goldman Sachs Group Inc. lifted its stake in shares of DENTSPLY SIRONA by 827.3% during the 1st quarter. Goldman Sachs Group Inc. now owns 2,434,925 shares of the medical instruments supplier’s stock worth $36,378,000 after acquiring an additional 2,172,343 shares during the last quarter. Empowered Funds LLC grew its position in DENTSPLY SIRONA by 8.8% in the 1st quarter. Empowered Funds LLC now owns 16,324 shares of the medical instruments supplier’s stock valued at $244,000 after acquiring an additional 1,320 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in DENTSPLY SIRONA by 7.5% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 593,021 shares of the medical instruments supplier’s stock worth $8,860,000 after purchasing an additional 41,579 shares during the period. Finally, Focus Partners Wealth lifted its position in shares of DENTSPLY SIRONA by 59.1% during the first quarter. Focus Partners Wealth now owns 25,181 shares of the medical instruments supplier’s stock worth $376,000 after purchasing an additional 9,355 shares during the last quarter. 95.70% of the stock is owned by hedge funds and other institutional investors.

About DENTSPLY SIRONA

Dentsply Sirona Inc (NASDAQ: XRAY) is a leading global manufacturer of professional dental products and technologies. The company, formed through the merger of Dentsply International and Sirona Dental Systems in February 2016, brings together a long heritage of innovation in dental care. Headquartered in Charlotte, North Carolina, Dentsply Sirona develops and markets a comprehensive range of dental consumables, laboratory products, and advanced imaging and CAD/CAM systems.

The company’s product portfolio spans preventive, restorative, orthodontic, endodontic and surgical care.